Key facts
- This page summarizes Robert E. Hoffman's Form 4 filing for Kintara Therapeutics, Inc. (HURA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Aug 2022, 16:30.
Robert E. Hoffman - 01 Aug 2022 Form 4 Insider Report for Kintara Therapeutics, Inc. (HURA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- HURA
- Reported as of
- 01 Aug 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Aug 2022, 16:30:30 UTC
- Prior SEC filing
- 17 Feb 2022
- Next SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Anthony Scott Praill, attorney-in-fact for Robert E. Hoffman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Hoffman filed Form 4 for Kintara Therapeutics, Inc. (HURA) on 03 Aug 2022.
Change
- Previous filing in this sequence was filed on 17 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KTRA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +400,145
- Change %
- +728%
- Price
- $0.000000
- Shares after
- 455,145
- Date
- 01 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KTRA
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +1,200,634
- Change %
- Price
- $0.000000
- Shares after
- 1,200,634
- Date
- 01 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,200,634
- Exercise price
- $0.1757
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023.
Footnote F2
The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter.